TNG908
- Generic Name
- TNG908
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
TNG908 is a small molecule inhibitor of protein arginine methyl transferase 5 (PRMT5).
- Associated Conditions
- -
- Associated Therapies
- -
Tango Therapeutics Reports Third Quarter 2024 Financial Results
Tango Therapeutics reports Q3 2024 financials, highlighting progress in PRMT5 inhibitor TNG462 clinical trials, including positive data in pancreatic and NSCLC. The company plans to advance TNG462 into combination trials with RAS(ON) inhibitors and other treatments, expecting enrollment in 1H 2025. TNG908 trial enrollment is halted to focus on TNG462. Tango also announces the appointment of Dr. Maeve Waldron-Lynch as SVP, Head of Clinical Development.
Wall Street Weighs Trump Effect on Biopharma, from Vaccines to M&A
Stock analysts predict significant shifts in biopharma due to Trump's election and Robert F. Kennedy Jr.'s potential role in healthcare, focusing on vaccine regulation and FDA leadership changes. Moderna's stock declines despite Q3 earnings, reflecting investor concerns over vaccine sentiment. Smaller biotechs may benefit from a more favorable M&A environment under Trump's administration.
Related Clinical Trials:
An SF5-Containing, Long-Acting, Potential Single Dose Malaria Cure from Novartis with a Novel MoA
TNG462, a PRMT5 inhibitor by Tango Therapeutics, is in Ph. I/II trial for MTAP-deleted solid tumors, designed to bind with MTA in these tumors, causing synthetic lethality. A CNS-permeable analogue, TNG908, is also being tested for MTAP-deleted glioblastoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath